FDA confirms SeaStar Medical fulfills QUELIMMUNE post-approval study requirements

Bitget2026/11/03 13:21

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

FDA determined SeaStar Medical's QUELIMMUNE fulfilled post-approval study requirements under its original Humanitarian Device Exemption.
Hospitals can now use QUELIMMUNE without registry infrastructure, expanding access for children with sepsis-associated acute kidney injury requiring renal replacement therapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seastar Medical Holding Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611030821PRIMZONEFULLFEED9868856) on November 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

FDA confirms SeaStar Medical fulfills QUELIMMUNE post-approval study requirements

You may also like

Crypto prices